Rilonacept Biosimilar – Anti-Interleukin-1 beta fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2021; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Rilonacept Biosimilar is a biologic drug that is designed to mimic the structure and function of the human protein interleukin-1 beta (IL-1β). It is a fusion protein, meaning it is made up of two different proteins that have been joined together. This biosimilar is a research grade version of the drug, meaning it is intended for use in laboratory research and not for clinical use.
Rilonacept Biosimilar is a fusion protein composed of two parts: the extracellular domain of the human IL-1β receptor and the Fc portion of a human antibody. The extracellular domain of the IL-1β receptor is responsible for binding to IL-1β, while the Fc portion of the antibody provides stability and prolongs the half-life of the drug in the body.
The IL-1β receptor is a transmembrane protein that is found on the surface of cells. It is composed of three subunits: IL-1R1, IL-1R3, and IL-1RAcP. The extracellular domain of the receptor is responsible for binding to IL-1β, while the intracellular domain activates signaling pathways within the cell.
Rilonacept Biosimilar works by binding to IL-1β and preventing it from interacting with the IL-1β receptor on cells. This prevents the activation of signaling pathways and the subsequent inflammatory response that IL-1β is known to cause.
IL-1β is a pro-inflammatory cytokine that is involved in a variety of immune and inflammatory responses. It is produced by immune cells in response to infection, injury, or other stimuli. However, excessive or prolonged production of IL-1β can lead to chronic inflammation and tissue damage.
By blocking the activity of IL-1β, Rilonacept Biosimilar has the potential to alleviate symptoms of inflammatory diseases such as rheumatoid arthritis, gout, and cryopyrin-associated periodic syndromes. It may also have applications in treating other conditions where IL-1β plays a role, such as cardiovascular disease and certain types of cancer.
The therapeutic target of Rilonacept Biosimilar is IL-1β, specifically its interaction with the IL-1β receptor. By targeting this specific interaction, the drug is able to block the activity of IL-1β without affecting other cytokines or immune functions.
The IL-1β receptor has been identified as a potential therapeutic target for a variety of inflammatory diseases. However, previous attempts at targeting this receptor have been hindered by the complexity and variability of IL-1β signaling. Rilonacept Biosimilar offers a more targeted approach by specifically blocking the binding of IL-1β to the receptor.
Rilonacept Biosimilar is currently being studied for its potential therapeutic applications in various inflammatory diseases. It is also being used in laboratory research to better understand the role of IL-1β in these diseases and to identify potential new targets for drug development.
In addition to its potential as a therapeutic agent, Rilonacept Biosimilar may also have applications in diagnostics and biomarker discovery. By selectively blocking the activity of IL-1β, researchers can study the effects of this cytokine on different cell types and in different disease states.
In summary, Rilonacept Biosimilar is a fusion protein designed to mimic the structure and function of the human protein IL-1β. It works by blocking the interaction between IL-1β and its receptor, thereby preventing the inflammatory response caused by IL-1β. This biosimilar has the potential to be used as a therapeutic agent for various inflammatory diseases and is also a valuable tool for research in this field.
ProteoGenix catalogue number PX-TA2021. For research use only.
Target: Rilonacept Biosimilar – Anti-Interleukin-1 beta fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Rilonacept Biosimilar – Anti-Interleukin-1 beta fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
